imeglimin (Twymeeg) Report issue

Small molecule Experimental
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Imeglimin is an oral anti-diabetic medication. It was approved for use in Japan in June 2021.   Wikipedia

Chemistry

  • SMILES: C[C@H]1N=C(N(C)C)N=C(N)N1
  • InChIKey: GFICWFZTBXUVIG-SCSAIBSYSA-N
  • Mol. Mass: 155.21
  • ALogP: -0.83
  • ChEMBL Molecule:
    imeglimin  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

imeglimin

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Diabetes Mellitus

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Heart (Phase 1)

Liver Diseases (Phase 1)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue